Chemical Works of Gedeon Richter (FRA:RIG2) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:RIG2 Chemical Works of Gedeon Richter PLC FRA:RIG2
93 GF Score
Price €33.20
GF Value €29.46
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Chemical Works of Gedeon Richter Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:RIG2
93GF Score
Chemical Works of Gedeon Richter PLC FRA:RIG2
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Chemical Works of Gedeon Richter (FRA:RIG2) Overvalued in 2026?

Based on GuruFocus' analysis, Chemical Works of Gedeon Richter stock appears to be overvalued. The current stock price of €33.20 is trading 12.7% above its estimated GF Value™ of €29.46. GuruFocus considers Chemical Works of Gedeon Richter to be Modestly Overvalued.

Key valuation signals for FRA:RIG2:

  • Dividends Received:
  • GF Value™: €29.46 vs. price of €33.20 (12.7% above fair value)
  • GF Score™: 93/100 with 5 warning signs

No single metric tells the full story. See the FRA:RIG2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Chemical Works of Gedeon Richter Business Description

Address Gyomroi ut 19-21, Budapest, HUN, 1103
Chemical Works of Gedeon Richter PLC is a pharmaceutical company. The company focuses on the development and manufacture of gynaecological, cardiovascular, and central nervous system products. It manufactures medicines including original, generic and licensed products for treatment in the therapeutic area. The group is active in two business segments namely, the Pharma segment comprising Women's Healthcare, Neuropsychiatry, Biotechnology, General Medicine, and Other pharma; and the Others segment includes the remaining wholesale and retail business of the Group and all other activities. The company operates internationally.
93GF Score

Get the complete analysis for FRA:RIG2

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€33.20
Price
€29.46
GF Value